ACM
ITOS

Asymmetry Capital Management’s iTeos Therapeutics ITOS Stock Holding History

Asymmetry Capital Management’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$4.88M Buy
104,755
+47,469
+83% +$1.58M 2.59% 18
2021
Q3 		$1.55M Sell
57,286
-3,962
-6% -$104K 0.93% 24
2021
Q2 		$1.57M Sell
61,248
-41,038
-40% -$978K 1.08% 24
2021
Q1 		$3.5M Sell
102,286
-36,098
-26% -$1.3M 1.81% 23
2020
Q4 		$4.68M Buy
138,384
+80,633
+140% +$2.13M 2.13% 18
2020
Q3 		$1.43M Buy
+57,751
New +$1.55M 0.92% 29

Other funds holding ITOS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Asymmetry Capital Management's ITOS Position: Q4 2021 in Review

Asymmetry Capital Management increased its iTeos Therapeutics (ITOS) stake by 83% in Q4 2021, buying an estimated $1.58M and bringing the position to 104,755 shares worth $4.88M. The position accounts for 2.59% of the portfolio, ranked #18.

Asymmetry Capital Management first reported a position in ITOS in Q3 2020 and has held it in 6 quarters since. 118 funds tracked by Wall St. Rank hold ITOS as of Q4 2021.

  • Asymmetry Capital Management held 104,755 shares of iTeos Therapeutics worth $4.88M as of Q4 2021.
  • Asymmetry Capital Management bought 47,469 iTeos Therapeutics shares in Q4 2021, an estimated $1.58M.
  • iTeos Therapeutics made up 2.59% of Asymmetry Capital Management's portfolio in Q4 2021, its #18 holding.
  • Asymmetry Capital Management first reported a position in iTeos Therapeutics in Q3 2020 and has held it in 6 quarters since.
  • 118 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q4 2021.

Based on Asymmetry Capital Management's 13F filing for Q4 2021, filed 19 Jan 2022.